A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age
Latest Information Update: 13 Oct 2025
At a glance
- Drugs LTG-001 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- Sponsors Latigo Biotherapeutics
Most Recent Events
- 29 Sep 2025 Planned End Date changed from 28 Sep 2025 to 28 Feb 2026.
- 29 Sep 2025 Planned primary completion date changed from 28 Jul 2025 to 28 Feb 2026.
- 29 Sep 2025 Status changed from recruiting to active, no longer recruiting.